| Ticker Details |
Veracyte, Inc.
Veracyte Inc is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity. The Company's first commercial solution, the Afirma Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier.
|
| IPO Date: |
October 30, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$4.73B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.64 | 2.70%
|
| Avg Daily Range (30 D): |
$1.42 | 2.73%
|
| Avg Daily Range (90 D): |
$1.11 | 2.72%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.41M |
| Avg Daily Volume (30 D): |
.99M |
| Avg Daily Volume (90 D): |
.8M |
| Trade Size |
| Avg Trade Size (Sh.): |
61 |
| Avg Trade Size (Sh.) (30 D): |
51 |
| Avg Trade Size (Sh.) (90 D): |
49 |
| Institutional Trades |
| Total Institutional Trades: |
3,860 |
| Avg Institutional Trade: |
$2.92M |
| Avg Institutional Trade (30 D): |
$5.68M |
| Avg Institutional Trade (90 D): |
$4.9M |
| Avg Institutional Trade Volume: |
.09M |
| Avg Institutional Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.41M |
| Avg Closing Trade (30 D): |
$16.59M |
| Avg Closing Trade (90 D): |
$10.56M |
| Avg Closing Volume: |
141.09K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$1.11
|
$.36
|
$.52
|
|
Diluted EPS
|
$1.08
|
$.35
|
$.5
|
|
Revenue
|
$541.74M
|
$139.07M
|
$140.64M
|
|
Gross Profit
|
$384.18M
|
$101.16M
|
$101.97M
|
|
Net Income / Loss
|
$88.01M
|
$28.71M
|
$41.15M
|
|
Operating Income / Loss
|
$77.52M
|
$22.65M
|
$37.2M
|
|
Cost of Revenue
|
$157.56M
|
$37.91M
|
$38.66M
|
|
Net Cash Flow
|
$77.03M
|
$-99.43M
|
$47.02M
|
|
PE Ratio
|
|
|
|
|
|
|
